Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diphenhydramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 7/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | SCN1A | P35498 | 3/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 3/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenhydramine SCHEMBL12543374 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL11795332 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL28210970 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL10487818 | 0.98 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL29205078 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL25219551 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL17071 | 0.98 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL9565209 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL27912373 | 0.96 | SLC6A2 (0.93) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL28268393 | 0.96 | SLC6A2 (0.93) | SLC6A2SLC6A4SLC6A3LMNACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 111584 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026105079-A2 | METHODS, THERAPIES AND USES FOR TREATING CANCER | PFIZER INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| WO-2026102141-A1 | COMPOSITIONS FOR PCSK9 GENE EDITING AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | VERVE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20260125486-A1 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT | GENENTECH, INC. (US) | 2026-05-07 | — | — | US | claimed |
| US-20260124300-A1 | COMBINATION TREATMENT OF AN ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND CHEMOTHERAPY | HOFFMANN LA ROCHE (US) | 2026-05-07 | — | — | US | claimed |
| EP-4734952-A1 | ORAL TABLET WITH IMPROVED UNIFORMITY OF CONTENT OF ACTIVES | Fertin Pharma A/S (DK) | 2026-05-06 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-4067988-A | 3-Phenyl-1,2,4-oxadiazole derivatives as antiinflammatory-antitussive agents | LABORATOIRES CASSENNE (FR) | 1978-01-10 | — | — | US | claimed |
| US-4007273-A | Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds | LEVINSON HAROLD N | 1977-02-08 | — | — | US | claimed |
| US-4006246-A | ANTIULCER, SECRETOLYTIC, ANTITUSSIVE, STIMULANT | BOEHRINGER INGELHEIM GMBH (DT) | 1977-02-01 | — | — | US | claimed |
| US-4004010-A | ANALGESIC, ANTITUSSIVE | BOEHRINGER INGELHEIM GMBH (DT) | 1977-01-18 | — | — | US | claimed |
| US-4000302-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-12-28 | — | — | US | claimed |
| US-3998960-A | ANALGESIC, ANTITUSSIVE, OPIATE ANTAGONIST | BOEHRINGER INGELHEIM GMBH (DT) | 1976-12-21 | — | — | US | claimed |
| US-3992542-A | Pharmaceutical compositions containing an N-(furyl-methyl)-6,14-(endoethano or endoetheno)-7α-hydroxyalkyl-tetrahydro-noroipavine or -northebaine and method of use | BOEHRINGER INGELHEIM GMBH (DT) | 1976-11-16 | — | — | US | claimed |
| US-3975368-A | OPIATE ANTAGONIST, ANALGESICE, ANTITUSSIVE | BOEHRINGER INGELHEIM GMBH (DT) | 1976-08-17 | — | — | US | claimed |
| US-3961066-A | ANALGESICS, ANTITUSSIVES | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-06-01 | — | — | US | claimed |
| US-3958002-A | ADMINISTERING | PIERRE FABRE S.A. (FR) | 1976-05-18 | — | — | US | claimed |